AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Saturday 14 November 2026
News from the 24 hours to Saturday morning, 14 November 2026.
Tone of the day
+5.5positive
+5.5
Relevant headlines39
Stories11
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by regulatory wins, with US approval of the Imfinzi bladder cancer regimen and a positive EU committee opinion on baxdrostat (Baxfendy). Reports of about 600 US sales job cuts under a $1.5B savings plan tempered the tone.
What drove it
- bladder cancer approval
- Baxfendy EU recommendation
- US sales job cuts
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 8 Nov | +6.0 | 7 |
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
| Sat 14 Nov | +5.5 | 39 |
11 stories · 39 headlines · strongest first
Pharma and healthcare on 14 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca reduces its US sales workforce by 600 positions −2.614 headlines today · Bloomberg reported AstraZeneca is cutting about 600 US sales roles under a $1.5bn savings plan. | ||
| −3.3 | Commercial role reductions reported in US. | |
| −3.3 | Staff reductions in respiratory sales, though tied to savings drive.} | |
| −3.3 | Marketing roles cut across two drug businesses. | |
| −2.5 | Sales job cuts as part of cost savings plan. | |
| −2.5 | Report of US sales job cuts. | |
| −2.5 | Sales staff reduced as savings programme proceeds. | |
| −2.5 | Report of US sales job cuts. | |
| −2.5 | Staff trimmed under cost-cutting programme. | |
| −2.5 | Sales staff reduced as savings programme proceeds. | |
| −2.5 | US jobs cut within large cost-saving overhaul. | |
| −2.5 | Report of US sales job cuts. | |
| −2.5 | Sales network reduced as part of savings plan. | |
| −2.5 | US jobs cut within large cost-saving overhaul. | |
| −1.7 | Sales positions removed to finance pipeline investment. | |
| FDA approves Imfinzi regimen for bladder cancer +9.97 headlines today · The FDA approved Imfinzi with Padcev in muscle-invasive bladder cancer patients. | ||
| +10.0 | Company's own notice of new US approval. | |
| +10.0 | US regulator approved bladder cancer treatment. | |
| +10.0 | Regulatory clearance of new bladder cancer combination expands product use. | |
| +10.0 | Regimen gains US approval in bladder cancer. | |
| +10.0 | Approval for patients unable to take cisplatin widens use. | |
| +10.0 | Company announcement of US approval for new Imfinzi regimen. | |
| +9.2 | Label expansion strengthens competition against Merck's rival drug. | |
| EU committee recommends AstraZeneca's Baxfendy for hypertension +8.87 headlines today · The CHMP recommended approval of AstraZeneca's baxdrostat, branded Baxfendy, for uncontrolled hypertension. | ||
| +10.0 | European committee recommends approval of new blood pressure drug. | |
| +9.2 | EU panel supports hypertension drug. | |
| +9.2 | Company says hypertension drug recommended for European approval. | |
| +9.2 | EU committee supports marketing authorisation for baxdrostat. | |
| +9.2 | Committee backs drug for uncontrolled high blood pressure. | |
| +9.2 | Hypertension drug recommended for European approval. | |
| +5.8 | EU backing for hypertension drug, with US pricing pressure noted. | |
| AstraZeneca acquires US biotech Omniose +7.22 headlines today · 23 in all, since 11 November · Coverage says the Omniose deal adds a bacterial vaccine platform. | ||
| +6.7 | Deal adds to run of favourable pipeline developments. | |
| +5.0 | Acquisition adds a bacterial vaccine platform. | |
| AstraZeneca valuation pieces +2.12 headlines today · Valuation articles ask whether AstraZeneca is still reasonably priced. | ||
| +2.5 | Valuation commentary noting cash flow supported by oncology. | |
| +1.7 | Valuation piece referencing strong long-term share performance. | |
| AstraZeneca market focus commentary +0.82 headlines today · Commentary pieces ask what is drawing market attention to AstraZeneca. | ||
| +0.8 | Generic watchlist commentary with little substance. | |
| +0.8 | Generic market commentary with little substance. | |
| AstraZeneca stock and oncology approvals +6.71 headline today · A piece asks whether new oncology approvals could lift AstraZeneca shares. | ||
| +6.7 | Approvals seen as widening commercial opportunity. | |
| SAP buyback and AstraZeneca bet linked to 28 January 2027 +2.91 headline today · 2 in all, since 13 November · AstraZeneca gave SAP a major cloud migration, with JPMorgan turning bullish. | ||
| +5.0 | Large cloud contract and bullish broker stance. | |
| AstraZeneca launches biomarker testing campaign +3.31 headline today · AstraZeneca has begun its Meet Your Mark campaign, which aims to make biomarker testing better known. | ||
| +3.3 | Awareness campaign on biomarker testing supports oncology franchise. | |
| AstraZeneca to move primary listing to NYSE +2.51 headline today · According to a report, AstraZeneca intends to move its principal listing to the NYSE during 2026. | ||
| +2.5 | Planned move of main listing to New York noted. | |
| AstraZeneca withdrew an EU application for an antibody; CHMP supported Gazyvaro for lupus +2.51 headline today · AstraZeneca pulled an EU filing for an antibody while CHMP backed Gazyvaro in lupus. | ||
| +2.5 | Lupus backing for one drug offset by withdrawn filing for another. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.